Doris Ponce is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 311 publications with 6,187 citations (h-index 32); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1233 York Ave
Sr 327
New York, NY 100656306
Telephone
212-639-4838Registry record last updated 17 Jan 2014.
Clinical trials
- A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Sponsor: Memorial Sloan Kettering Cancer Center
- A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
Sponsor: Seres Therapeutics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202516 payments$22,616openpaymentsdata.cms.gov ↗
- SANOFI PASTEUR INC.Program year20252 payments$19,115openpaymentsdata.cms.gov ↗
- SANOFI-AVENTIS U.S. LLCProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Intestinal microbiome restoration in allogeneic stem cell transplantation
Sloan-Kettering Inst Can Research
FY2026$442,500R01HL164902 - Microbiome manipulation through oral live biotherapeutic product (LBP) for the treatment of gut acute graft-versus-host disease (GVHD)
Sloan-Kettering Inst Can Research
FY2026$281,722R34HL184529 - Intestinal microbiome restoration in allogeneic stem cell transplantation
Sloan-Kettering Inst Can Research
FY2025$442,500R01HL164902
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease
Cell Host & Microbe
2024 - Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era
Bone Marrow Transplantation
2024 - EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation
2023 - Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse
Science Translational Medicine
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”